Entresto, a medication used to treat heart failure, is currently protected by patents, meaning a generic version is not yet available. The earliest potential generic availability for Entresto is anticipated around 2028 [1]. However, patent challenges and the complex nature of drug patents can influence this timeline, with some sources indicating possible generic entry as late as 2030 or later depending on litigation outcomes [2].
Why are companies challenging Entresto's patents?
Pharmaceutical companies often challenge existing patents to pave the way for their own generic versions of a drug. By invalidating or finding workarounds for these patents, generic manufacturers aim to enter the market earlier. This strategy can lead to significant litigation as the innovator company defends its intellectual property [3].
How do patents affect generic drug availability?
Patents grant the inventor of a drug exclusive rights to sell it for a specified period, typically 20 years from the filing date. During this patent protection period, generic versions of the drug cannot be legally manufactured or sold. Once the patents expire, or if they are successfully challenged, generic manufacturers can apply to the U.S. Food and Drug Administration (FDA) for approval to market their versions of the drug, often leading to lower prices [1].
What is the significance of the 2028 date for Entresto generics?
The year 2028 is frequently cited as the earliest potential expiration of key patents protecting Entresto. This date represents a critical juncture where the market could open up for generic competition, provided no further patent extensions or successful legal challenges alter the landscape [1][2].
Can Entresto be used for conditions other than heart failure?
Entresto is approved for specific types of heart failure, primarily heart failure with reduced ejection fraction (HHFmrEF). Its efficacy and safety are established within these indications. Research may explore its use in other cardiovascular conditions, but current regulatory approvals are focused on heart failure treatment [4].
How does Entresto work?
Entresto, also known by its chemical name sacubitril/valsartan, is a combination medication. It works by blocking the body's natural systems that can worsen heart failure. Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides, which help the body remove excess salt and water and dilate blood vessels. Valsartan is an angiotensin II receptor blocker (ARB), which prevents angiotensin II from constricting blood vessels and stimulating salt and water retention [4].
What are the risks associated with taking Entresto?
Common side effects of Entresto can include low blood pressure, high potassium levels, dizziness, and kidney problems. Patients with a history of angioedema or those taking certain other medications, like ACE inhibitors, may face increased risks. It is crucial for patients to discuss their medical history and any concerns with their healthcare provider [5].
Are there alternatives to Entresto for heart failure treatment?
Yes, there are several classes of medications used to treat heart failure, depending on the specific type and severity. These include ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors. The choice of treatment is individualized and determined by a physician based on the patient's condition [4].
What is the typical cost of Entresto?
The cost of Entresto without insurance can be substantial, often in the range of several hundred dollars per month. However, insurance coverage and patient assistance programs can significantly reduce out-of-pocket expenses for eligible individuals [6]. The availability of generic versions is expected to lead to a considerable decrease in price once they enter the market.
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] DrugPatentWatch.com
[4] Novartis (Manufacturer of Entresto)
[5] U.S. Food & Drug Administration (FDA)
[6] GoodRx